LAKE OSWEGO, Ore.--(BUSINESS WIRE)--BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced today that the Food and Drug Administration (FDA) has approved a significant expansion of its ongoing ProMRI® trial. The approval will allow patients enrolled in Phase C of the trial to receive full-body scans, and for the first time include patients with DX implantable cardioverter defibrillators (ICDs) in the study.
Help employers find you! Check out all the jobs and post your resume.
